ATA Thyroid Cancer

Memorial Sloan Kettering Cancer Center’s experience shows that selected patients with low-risk papillary thyroid cancer can safely defer surgery in favor of active surveillance.

In this interview we discuss which distant metastases in thyroid cancer are appropriate targets for I-131 treatment, appropriate dosing, and more.

Dual inhibition of PI3K signaling and histone deacetylase 2 (HDAC2) enzymes with CUDC-907 slowed thyroid tumor cell proliferation, tumor progression and metastasis, according to a preclinical study.